Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet 5/23 2012, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a Janssen Pharmaceuticals supplemental NDA for Xarelto (rivaroxaban) to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome [ST elevation myocardial infarction, non-ST elevation myocardial infarction, or unstable angina] in combination with aspirin alone or with aspirin plus clopidogrel or ticlopidine. Contact Kristina Toliver, (301) 796-9001. To view this notice, click here.